Gerald L. Klein, MD, has spearheaded numerous clinical trials as a PI before founding a SMO and CRO, where he served as CEO and CMO. Following the CRO's acquisition by Quintiles (now IQVIA), Dr. Klein became an SVP at Quintiles in Drug Development and Medical Affairs. He co-founded Pathway Diagnostics, Klein Medical News Service, Entera Health, and currently is a Principal at MedSurgPI LLC. His executive experience extends to roles like CEO, CMO, SVP, and VP in various companies, including Dey/MerckKgAa, Specialty Labs, Talecris/Grifols, Oxygen Biotherapeutics/Tanex, and Pathway Diagnostics. Dr. Klein serves on the Board of Directors for several biotech firms.
Academically, Dr. Klein is an Adjunct Professor in Pharmacology at East Carolina University's Brody School of Medicine and a former Professor at the University of California, Irvine. He has published extensively, including peer-reviewed articles, a textbook chapter, presentations, white papers, educational materials, and blogs.